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ABSTRACT 
 
Background: National guidelines state that patients with breast cancer undergoing mastectomy in 
England should be offered immediate breast reconstruction (IR), unless precluded by their fitness for 
surgery or the need for adjuvant therapies.   
Methods: A national study investigated factors that influenced clinicians’ decision to offer IR, and 
collected data on case mix, operative procedures and reconstructive decision-making among women 
with breast cancer having mastectomy with or without IR in the English National Health Service 
between 1 January 2008 and 31 March 2009.  Multivariable logistic regression was used to examine 
the relationship between whether or not women were offered IR and their characteristics (tumour 
burden, functional status, planned radiotherapy, planned chemotherapy, perioperative fitness, obesity, 
smoking status and age). 
Results: Of 13 225 women, 6458 (48.8 per cent) were offered IR.  Among factors the guidelines 
highlighted as relevant to decision-making, the three most strongly associated with the likelihood of 
an offer were tumour burden, planned radiotherapy and performance status.  Depending on the 
combination of their values, the probability of an IR offer ranged from 7.4 to 85.1 per cent.  A 
regression model that included all available factors discriminated well between whether or not women 
were offered IR (c-statistic 0.773), but revealed that increasing age was associated with a fall in the 
probability of an IR offer beyond that expected from older patients’ tumour and co-morbidity 
characteristics.     
Conclusion: Clinicians are broadly following guidance on the offer of IR, except with respect to 
patients’ age.  
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Introduction 
The breast is the most common form of cancer for women in England1.  Most women are diagnosed at 
an early stage, and undergo surgery to remove part (breast-conserving surgery) or all (mastectomy) of 
the breast. Patients with breast cancer often also have adjuvant treatments such as chemotherapy, 
radiotherapy and endocrine therapy.  Mastectomy may be a primary treatment, following preoperative 
or neoadjuvant chemotherapy, or a completion procedure after failed breast-conserving surgery2.  
Breast reconstruction may be undertaken at the time of mastectomy (immediate) or at a later date 
(delayed). The rate of immediate breast reconstruction (IR) in England has increased substantially, 
from 7 per cent in 1997 to 23 per cent in 20133,4.  Similar changes have been observed in other 
countries5,6.  Increasing IR rates may be related to improving breast cancer treatments, more effective 
reconstructive techniques, greater emphasis on aesthetic outcomes, and increased availability of 
appropriately trained surgeons and funding7,8. 
The National Institute for Health and Care Excellence (NICE)9 published early breast cancer 
guidelines in 2002 stating that surgeons should discuss breast reconstruction with all patients and that 
it should be available at the initial surgical operation.  Revised 2009 NICE guidelines10 clarified that 
women undergoing mastectomy should all be provided with information about reconstruction, and that 
IR should be offered where not precluded by patients’ fitness for surgery or an urgent need for 
adjuvant therapy.  A 2011 NICE quality standard11 confirmed that commissioners, providers and 
clinicians should ensure that IR is discussed with all patients with early breast cancer undergoing a 
mastectomy. 
Previous studies have identified age discrimination in the management of early breast cancer, 
with a 2015 review12 reporting a decline in both survival and the use of surgical and adjuvant 
treatments in older women.  However, there is limited information on the extent to which patient age 
influences an IR offer.  Several studies13–15 have examined the offer of IR, but all were undertaken at 
single specialist centres and the data cannot be generalized safely.  Two of these studies13,15 also 
examined the reasons given for an offer not being made, but neither used multivariable analysis to 
determine their relative importance.   
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This type of analysis cannot be undertaken using administrative data, as these code only the 
uptake of an IR offer rather than its receipt.  Information on whether an offer is made is important as it 
allows evaluation of whether or not IR can be accessed equitably within a healthcare system.  
Although older women may be presumed, other things being equal, to be less likely to take up an offer 
of IR, it is possible that inconsistent clinician behaviour also explains some of the age-related 
differences in IR uptake15.  National guidelines indicate that increasing age on its own should not 
preclude an IR offer.  However, age discrimination has been reported with respect to breast cancer 
treatments and breast cancer surgery in particular, both in England and internationally16–18. 
For these reasons, a national prospective study was undertaken to determine the proportion of 
women with breast cancer undergoing mastectomy in the English National Health Service (NHS) who 
were offered IR, and to examine how its likelihood was related to women’s demographic and clinical 
characteristics.  
 
Methods 
The study used data submitted prospectively by all 150 English NHS acute hospital trusts during a 
national clinical audit7.  The audit protocol and reports are available for review at: 
http://www.rcseng.ac.uk/standards-and-research/research/clinical-effectiveness-unit/documents-
publications. National cancer audits are exempt from the UK National Research Ethics Committee 
approval process. 
This study analysed the data from women (aged 16 years or over) diagnosed with breast 
cancer or ductal carcinoma in situ (DCIS), and who had unilateral mastectomy with or without IR over 
a 15-month interval, between 1 January 2008 and 31 March 2009.  Information was collected on age 
at surgery and other prognostic variables that were expected to influence surgical decision-making, 
and possibly confound the relationship between age and access to IR.  These included: tumour burden 
(invasive status and Nottingham Prognostic Index (NPI) score), smoking status, obesity, diabetes, and 
two measures of physical function: ASA grade of perioperative fitness and Eastern Cooperative 
Oncology Group (ECOG) functional status score19.  Information was also collected on procedure type 
(mastectomy alone or mastectomy with IR) and planned adjuvant treatments (chemotherapy and 
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radiotherapy).  For women who had not undergone IR, information was collected from the clinician on 
whether or not they were offered the procedure.  This last variable reflected clinicians’ decision-
making but did not incorporate patient preference.  For the present study, only women with complete 
information recorded on all of these variables were included in the analyses. 
 
Statistical analysis 
The proportion of women offered IR overall and among groups with different characteristics was 
calculated.  The statistical significance of differences between group proportions was assessed using 
the 2 test.   
Two logistic regression models were developed to examine the relationship between patient 
characteristics and planned treatments and the IR offer rate.  The first incorporated only clinical 
factors that were consistent with the NICE guidance on which women should be offered IR (physical 
health and planned adjuvant therapy), and was used to explore how the dominant factors influenced 
the IR offer rates across different patient groups.  As part of this process, tumour burden was defined 
using four categories: DCIS and invasive with good (NPI under 3.4), moderate (NPI 3.4–5.4) or poor 
(NPI over 5.4) prognosis.  The second model was developed using both sociodemographic and clinical 
factors that might influence the decision to offer IR.  This model included age at time of surgery, 
which was added as a continuous variable.  To aid interpretation, the adjusted odds ratio associated 
with age was presented per year increase in age.  The performance of both models was summarised 
using the c-statistic, a measure of a logistic regression model’s ability to discriminate between which 
women would and would not be offered IR20.  
All statistical tests were two-sided and P < 0.050 was considered to indicate a significant 
result.  STATA® version SE 11 (StataCorp, College Station, Texas, USA) and Microsoft Excel® 2010 
(Microsoft, Redmond, Washington, USA) software were used for all analyses.  
 
Results 
Between 1 January 2008 and 31 March 2009, the audit registered 14 811 women with breast cancer or 
DCIS who underwent mastectomy with or without IR at 150 English NHS Trusts. Some 1586 women 
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for whom one or more data items were missing in the data set were excluded.  After exclusions, a 
total of 13 225 women with complete data were included in the cohort, of whom 10 625 underwent 
mastectomy alone and 2600 (19.7 per cent) had IR.  The final sample with complete data included in 
the analyses appeared representative; the women excluded owing to incomplete data had similar 
characteristics to those included in the study (mean age 59.3 versus 61.0 years respectively; 
proportion with invasive disease 85.2 versus 84.8 per cent). 
 
Univariable analyses 
Over the study interval, 6458 women (48.8 per cent) in the mastectomy cohort were offered IR.  Table 
1 shows the proportion of women who received an offer of IR stratified by various demographic and 
clinical characteristics.  Increasing age, obesity, reduced perioperative fitness (ASA grade), impaired 
functional status (ECOG score), greater tumour burden, and planned adjuvant radiotherapy and 
chemotherapy were all significantly associated with a lower IR offer rate. 
 
Multivariable regression analyses  
Among the factors directly relevant to the NICE guideline recommendations, the three most strongly 
related to an IR offer were tumour burden, ECOG performance status and planned radiotherapy.  The 
effect of each factor was in the direction consistent with the NICE guidance (Table 2), and there were 
substantial differences in the proportion of women offered IR within the eight patient groups defined 
by combining these three factors.  The observed proportions ranged from 7.4 to 85.1 per cent (Fig. 1).   
Predicted IR rates for the individual groups were derived using the first (exploratory) logistic 
regression model that included only these three factors.  There was a reasonable correspondence 
between the predicted and observed IR rates for the groups, with the exception of women with DCIS 
and no functional impairment having planned radiotherapy (Fig. 1).  This exploratory model 
performed reasonably well at discriminating between the individual women to whom clinicians did 
and did not offer IR (c-statistic = 0.748).   
The results from the second regression model, which included five additional clinical and 
patient factors, are shown in Table 2.  Four of these factors can be regarded as being relevant to the 
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NICE guidance because they are associated with a patient’s fitness for surgery; the exception is age.  
This model demonstrated slightly improved performance and discrimination compared with the 
exploratory model (c-statistic = 0.773).  The odds ratios associated with the three factors in the 
exploratory model changed by varying degrees with the inclusion of these five additional items.  The 
odds ratios associated with the tumour groups changed marginally, but the effect of the ECOG 
performance status categories was reduced following inclusion of other factors associated with 
physical function (ASA grade, obesity, smoking).  The effect of radiotherapy was increased slightly 
following inclusion of these additional factors, with the estimated odds ratio falling from 0.42 to 0.36.     
Age demonstrated a strong and persistent effect, even after adjustment for the other factors 
associated with physical function. The effect of age was explored by using the regression model to 
predict the probability of each woman being offered IR given their clinical characteristics, but 
assuming they were of mean age (61.0 years).  The difference between the predicted and observed IR 
rates was plotted for women in different age groups (Fig. 2), showing that the IR offer rate fell further 
with age than would be anticipated based on concurrent changes in tumour burden and physical 
function.  
  
Discussion 
Clinical guidelines indicate that an offer of IR with mastectomy should be based on tumour 
characteristics and fitness for surgery. The results of the present study confirm that clinicians take into 
account tumour burden, physical function and whether or not chemotherapy and radiotherapy are 
anticipated when deciding to offer IR. An offer of IR was not always made to some women who 
appeared to be fit and who were not expected to require adjuvant therapy.  Patients’ age was 
independently associated with clinicians’ decision to offer IR, despite national guidelines not 
specifying this as a factor. The strengths of this study include its large size, the representative sample 
of patients undergoing mastectomy7, and its prospective design3, allowing consideration of specific 
questions about whether or not a reconstructive offer was made. 
The study also has limitations. The data were collected between 2008 and 2009, and clinical 
practice might have altered to some degree in the intervening years.  The size of any change is likely 
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to have been small, however, as the evidence base and recommendations about breast reconstruction 
have changed minimally.  In addition, IR rates have not changed substantially over the intervening 
time within England4.  Although new types of IR have been introduced (such as autologous fat 
transfer, dermal flaps, acellular dermal matrix-assisted implants), their indications are similar to those 
of the techniques used during the study interval. 
The NPI score used to stratify women into tumour groups was available to the clinician only 
after surgery19.  Clinicians therefore made IR offers and planned adjuvant therapies based on 
incomplete information about tumour burden.  This might have accounted for some of the differences 
between the observed IR offer rate and that predicted by the models.  However, planned adjuvant 
radiotherapy and chemotherapy were included in the models to address this issue. Neoadjuvant 
chemotherapy was not included, as its delivery could not be affected or delayed by a subsequent IR 
procedure.   
The impact of the diagnostic pathway (screening or symptomatic) on IR offer rates was not 
investigated.  Older women are more likely to present symptomatically, less likely to be treated 
surgically, and are more likely to undergo mastectomy12,16,21.  Although these factors were included in 
the regression model, it is still possible that the diagnostic pathway had an independent influence on 
IR offer rates, which has not been accounted for. In addition, the observed age effect might reflect 
unmeasured levels of poor fitness for surgery. Finally, the study relied on clinicians giving honest 
responses about their decision-making.  The reported reconstructive decision-making was consistent 
with the subsequent pattern of care overall, but the possibility of social desirability bias or inaccurate 
responses cannot be discounted. 
Most evidence on clinical decisions to offer IR with mastectomy is from single-centre studies, 
and provides a patchy view on factors that influence this decision. Population-based studies are rare. A 
prospective study13 in Australia found that the four surgeons in a single centre focused primarily on 
the need for postmastectomy radiotherapy when deciding whether or not to offer IR.  Studies at single 
centres in the USA14 and South Africa15 have reported a broader range of clinical factors influencing 
decisions to offer reconstruction, including cancer stage, axillary nodal status, smoking status, body 
habitus, pre-existing scars, and planned or previous radiotherapy or chemotherapy.  Two qualitative 
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studies22,23 suggested that decisions were also influenced by prompt access to a full range of 
reconstructive choices. 
Other studies have examined whether clinician characteristics might predict the likelihood of 
an IR offer being made.  Some24–27 suggested that surgeons’ age, sex and training background 
influenced decision-making.  A French study28 found that the characteristics of the treating surgeon 
were highly predictive of an IR offer, with patient co-morbidities being less important.  Another North 
American study29 reported preoperative counselling by the breast surgeon and preoperative review by 
a plastic surgeon being strongly associated with an offer of IR, with 91 per cent of those referred to a 
plastic surgeon proceeding to IR.  This study also identified increasing patient age as being related to 
lower rates of reconstructive offer. 
For patients undergoing mastectomy in England, the likelihood of an IR offer is broadly 
associated with their tumour burden, planned treatments and physical fitness.  Nonetheless, a 
significant proportion of women without fitness-for-surgery issues or a need for urgent adjuvant 
therapy are still not offered IR.  In particular, the likelihood of an offer decreases sharply once a 
woman is aged 70 years or more.  This does not reflect the current national guidance.  There are a 
number of possible reasons for this last finding, which clinicians should consider and address.   
Increased age may also be seen as a proxy for fitness and associated with worse outcomes, despite a 
lack of evidence for this. It may reflect rationing within a national healthcare system with limited 
resources and waiting time pressures, or reflect the broader tendency for clinicians to offer fewer 
treatments to older patients with cancer16–18.  Finally, older women may be assumed by clinicians to 
not be interested in breast reconstruction. This last reason highlights the relationship between offer 
decisions and reconstructive uptake, another area about which little is currently known.  Additional 
work should be undertaken to examine uptake of reconstruction and the role of patient preferences 
once an offer is made. 
Overall, these results suggest a need for clinicians to audit their own (and their organization’s) 
decision-making processes around offering IR, and to deal with any age bias found to be present.  This 
will require clinicians to document their decision-making regarding offering access to IR; the present 
study demonstrates that this is possible.  There is also a need for standardized patient assessment tools 
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to guide breast cancer multidisciplinary teams during reconstructive decision-making30 and to support 
the benchmarking of IR offer rates.  The regression models developed here suggest that it is possible 
to develop a robust and clinically appropriate audit tool that can take account of differences between 
patients, and so enable like-for-like comparisons across hospitals and regions within countries. 
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Fig. 1 Patterns of immediate breast reconstruction (IR) offer based on three most dominant 
clinical factors: tumour burden, planned radiotherapy treatment and physical health (Eastern 
Cooperative Oncology Group (ECOG) score). DCIS, ductal carcinoma in situ; NPI, 
Nottingham Prognostic Index  
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Fig. 2 Observed rates of immediate breast reconstruction (IR) offer by age at surgery 
compared with predicted IR offer rate from model 2 (clinical and patient characteristics) with 
the effect of age removed (held constant at the mean age for the group) 
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Table 1 Number and proportion of patients undergoing mastectomy to receive an offer of immediate 
reconstruction, stratified by sociodemographic and clinical characteristics 
 No. of 
mastectomies 
No. offered IR 
P* 
Age (years)   < 0.001 
< 40 677  393 (58.1)  
40–49 2364 1400 (59.2)  
50–59 3036 1866 (61.5)  
60–69 3286 1800 (54.8)  
70–79 2494  810 (32.5)  
≥ 80  1368  189 (13.8)  
Smoking status   0.398 
Non-smoker 11 405 5586 (49.0)  
Current smoker 1820  872 (47.9)  
BMI   < 0.001 
Not obese 9575 4909 (51.3)   
Obese 3650 1549 (42.4)  
ASA fitness grade   < 0.001 
I 6262 3806 (60.8)   
II 5495 2394 (43.6)  
III or IV 1468  258 (17.6)  
ECOG score   < 0.001 
0 8895 5239 (58.9)  
1 2574  962 (37.4)  
≥ 2  1756  257 (14.6)  
Tumour burden   < 0.001 
DCIS 2016 1463 (72.6)  
Invasive, NPI < 3.4 2078 1219 (58.7)  
Invasive, NPI 3.4–5.4 5591 2610 (46.7)  
Invasive, NPI > 5.4 3540 1166 (32.9)  
Planned radiotherapy   < 0.001 
No 8100 4718 (58.2)  
Yes 5125 1740 (34.0)  
Planned chemotherapy   0.001 
No 8628 4305 (49.9)  
Yes 4597 2153 (46.8)  
Overall  13225 6458 (48.8)  
Values in parentheses are percentages. IR, immediate breast reconstruction; ECOG, Eastern 
Cooperative Oncology Group; DCIS, ductal carcinoma in situ; NPI, Nottingham Prognostic Index. *2 
test. 
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Table 2 Adjusted odds ratios from logistic regression analysis for offer of immediate breast 
reconstruction for women with various clinical and sociodemographic characteristics 
 
 Odds ratio 
Model 1  
(main factors) 
 
Model 2  
(clinical and patient characteristics) 
Tumour group    
DCIS 1.00 (reference)  1.00 (reference) 
Invasive,  NPI < 3.4 0.58 (0.51, 0.67)  0.62 (0.54, 0.72) 
Invasive, NPI 3.4–5.4 0.43 (0.38, 0.48)  0.48 (0.43, 0.55) 
Invasive,  NPI > 5.4 0.31 (0.27, 0.36)  0.35 (0.30, 0.40) 
ECOG score    
0 1.00 (reference)  1.00 (reference) 
1 0.40 (0.36, 0.43)  0.62 (0.56, 0.69) 
≥ 2  0.11 (0.09, 0.12)  0.26 (0.22, 0.31) 
Planned adjuvant radiotherapy (yes versus no) 0.42 (0.39, 0.46)  0.36 (0.33, 0.39) 
Planned adjuvant chemotherapy (yes versus no)   0.86 (0.79, 0.95) 
ASA fitness grade    
I   1.00 (reference) 
II   0.84 (0.76, 0.92) 
III or IV   0.47 (0.39, 0.56) 
BMI (obese versus not obese)   0.83 (0.76, 0.90) 
Current smoker (versus non-smoker)   0.78 (0.70, 0.88) 
Age (years) (linear)   0.96 (0.96, 0.97) 
Values in parentheses are 95 per cent confidence intervals.  
Area under receiver operating characteristic (ROC) curve (c-statistic) was 0.748 and 0.773 in models 
1 and 2 respectively.  
DCIS, ductal carcinoma in situ; NPI, Nottingham Prognostic Index; ECOG, Eastern Cooperative 
Oncology Group.  
 
